Journal of Capital Medical University ›› 2018, Vol. 39 ›› Issue (2): 243-251.doi: 10.3969/j.issn.1006-7795.2018.02.017

Previous Articles     Next Articles

Effects of Jiedu medicine combined with Liangxue medicine on mice psoriasis-like lesions induced by imiquimod

Zhai Chunyan1,2, Di Tingting2, Zhao Jingxia2, Wang Yan2, Xie Xinran2, Li Xue2,3, Meng Yujiao2,3, Li Ningfei2,3, Liu Zhengrong2,3, Zhang Lu2, Zhang Lei2, Wang Ning2, Li Ping2   

  1. 1. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China;
    2. Beijing Key Laboratory of Clinic and Basic Research with Traditional Chinese Medicine on Psoriasis, Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China;
    3. Beijing Hospital of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100027, China
  • Received:2017-12-19 Online:2018-03-21 Published:2018-04-14
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81330065).

PDF

72

Abstract: Objective To observe the effects of Liangxue Jiedu (LXJD) decoction and Liangxue(LX)decoction on mice psoriasis-like lesions induced by imiquimod (IMQ), and further explore the the mechanism of compatibility of Jie Du medicine in psoriasis.Methods BALB/c mice (n=55) were randomly divided into 5 groups:control group, model group, LX groups, LXJD groups, and methotrexate (MTX) group. The model was induced by 5% IMQ daily. On day 7, to observe the psoriasis area and severity index(PASI) and score, observed lesions morphological changes and epidermal layer thickness under light microscope; The skin barrier function was evaluated by testing oil and water component in the skin. The histology and epidermal thicknesses were observed under high microscope. The expressions of proliferating cell nuclear antigen (PCNA) and CD3 were detected by immunohistochemical staining. And detecting interleukin-17 (IL-17) mRNA,IL-23 mRNA andIL-1β mRNA were detected by RT-PCR. Results The cutaneous symptoms were alleviated in LX and LXJD groups compared with those in model group accompanied with PASI scores decreased; the means of epidermis thickness in LX and LXJD groups were less than that in model group; compared with model group,the percentages of PCNA positive cells and the numbers of CD3 positive cells in LX and LXJD groups were reduced(P<0.05); meanwhile, the relative expressions of IL-1β mRNA in LX and LXJD groups were decreased compared with that in model group(P<0.05). In the above indexes, LXJD group was better than LX group(P<0.01). In addition the LXJD decoction can make the moisture content (16.980±2.739) and oil content (7.750±1.209) in the lesions of mice increased (P<0.05). The relative expression of IL-17 and IL-23 mRNA also decreased (P<0.05). In some indexes like PASI scores, epidermis thickness, the percentages of PCNA positive cells (5.66±0.057) and the numbers of CD3 positive cells (10.670±0.193), LXJD group was better than LX group (P<0.01). Conclusion LXJD decoction and LX decoction can inhibit the expression of IL-1 β, reduce inflammatory infiltration and thereby improving imiquimod-induced mice psoriasis-like lesions. Jiedu medicine may play a crucial role through the inflammatory axis of IL-17 and IL-23 on LXJD group which can better alleviate psoriasis like lesions and further improve the skin barrier function. It is suggested that the inhibitory effect of the Jie Du medicine on the related inflammatory factors may be a potential mechanism for the treatment of psoriasis.

Key words: psoriasis, Liangxue decoction, Liangxue Jiedu decoction, interleukin-17, interleukin-23

CLC Number: